# US 2017/0253939 A1 · Method for detecting and typing high-risk human papillomaviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253939 A1
- Document ID: US20170253939A1
- Status: Published application
- Kind: A1
- Application number: 15/506,988
- Filed: 2015-08-28
- Published: 2017-09-07
- Earliest claimed: 2014-08-28
- Assignees: Hangzhou DALTON BioSciences, Ltd.
- Applicants: Hangzhou DALTON BioSciences,Ltd.
- Inventors: Shaobing HUA; Jiefeng HU; Xufeng ZHU; Yingjia SHOU; Deqiang LI; Shuanlin WEI; Bin HAN
- Web page: https://patentgrep.com/patent/US20170253939A1

## CPC

- C12Q 1/708: {for papilloma}
- C12Q 1/6804: Nucleic acid analysis using immunogens (immunoassay G01N33/53)
- C12Q 1/6816: characterised by the detection means (C12Q1/6804 takes precedence)
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a method for detecting and typing high-risk human papillomavirus (HPV). A probe having a specific detection function for 14 types of high-risk HPV is disclosed, and a technology capable of detecting and typing high-risk HPV DNA is developed on the basis of a nucleic acid hybridization chemiluminescence immunoassay technology.

## Claims

### Claim 1

A kit for high-risk HPV detection, wherein the kit comprises: virus-specific RNA probes targeted at HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.

### Claim 2 (depends on 1)

The kit according to claim 1, wherein the said virus-specific RNA probes targeted at HPV16 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 83-1558, 3193-4628, 5559-7154 of Genbank accession number k02718, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV18 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 105-1593, 2376-3867, 5430-7136 of Genbank accession number X05015, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV31 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 108-1463, 3564-4982, 5558-7072 of Genbank accession number HQ537666, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV33 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 109-1654, 3789-5087, 5594-7093 of Genbank accession number M12732, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV35 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 110-1476, 3452-4897, 5601-7109 of Genbank accession number X74477, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV39 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 107-1608, 2654-4187, 5643-7160 of Genbank accession number M62849, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV45 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 102-1543, 3421-4872, 5530-7149 of Genbank accession number X74479, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV51 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 68-1476, 2875-4452, 5894-7431 of Genbank accession number M62877, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV52 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 89-1565, 2459-4098, 5565-7154 of Genbank accession number X74481, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV56 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 102-1567, 2432-3896, 5492-7096 of Genbank accession number X74483, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV58 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 110-1542, 2763-4389, 5565-7139 of Genbank accession number D90400, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV59 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 55-1398, 3567-4896, 5606-7132 of Genbank accession number X77858, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV66 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 67-1534, 2679-4231, 5647-7158 of Genbank accession number U31794, or the RNA sequence complementary to the said DNA sequence;
wherein the said virus-specific RNA probes targeted at HPV68 is a RNA sequence including the RNA sequence corresponding to the DNA sequences of 150-1678, 2986-4476, 5508-7025 of Genbank accession number FR751039, or the RNA sequence complementary to the said DNA sequence.

### Claim 3 (depends on 1)

The kit according to claim 1, wherein the kit comprises: the probe reagent A: which comprises HPV16 and 18-type specific RNA probes;
the probe reagent B: which comprises HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68-type specific RNA probes;
Capture antibody, which is a specific antibody against DNA-RNA heterozygote, wherein the said antibody is contained in a solution or fixed on a solid-phase carrier; and
The detection antibody, which is a specific antibody against DNA-RNA heterozygote, and is linked with a detectable signal.

### Claim 4 (depends on 1)

The kit according to claim 1, wherein the kit further comprises one or more reagents selected from the following groups:
High-risk HPV quality control product;
Low-risk HPV quality control product;
A washing liquid;
Denaturing liquid;
Reagent that identifies a detectable signal; and/or
A micro-pore plate;
Preferably, the said detectable signal is selected from: alkaline phosphatase, horseradish peroxidase, glucose oxidase, beta-D-galactosidase, urease, catalase, or glucoamylase; the reagents for identifying the detectable signal are the substrates of alkaline phosphatase, horseradish peroxidase, glucose oxidase, beta-D-galactosidase, urease, catalase, or glucoamylase.

### Claim 5 (depends on 4)

The kit according to claim 4, wherein the said high-risk HPV quality control product comprises:
The high-risk HPV low-value quality control product A: which is a solution containing 1 pg/ml HPV16 DNA; the high-risk HPV low-value quality control product B: which is a solution containing 1 pg/ml HPV58 DNA; the high-risk HPV high-value quality control product A: which is a 5 pg/ml HPV16 DNA solution; and a high-risk HPV high-value quality control substance B: a solution containing 5 pg/ml HPV58 DNA; or
The low-risk type HPV quality control product is a solution containing 5 pg/ml HPV6 DNA.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 1)

A detecting method for high-risk HPV, wherein the method comprises the following steps: detecting a sample to-be-detected with the kit according to claim 1 to judge the existence of the high risk type HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68;

### Claim 9

(canceled)

### Claim 10 (depends on 8)

The method according to claim 8, wherein the typing method is as follows:
If the detectable signals on the solid-phase carriers A and B are both “positive”, it indicates that the sample to-be-tested contains one or more of HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and also contains one or two of HPV16 and 18;
If only the detectable signal on the solid-phase carrier A is a “positive” signal, it indicates that the to-be-detected sample to be detected contains one or two of HPV16 and 18; and
If only the detectable signal on the solid-phase carrier B is a “positive” signal, it indicates that the sample to-be-detected contains one or more of HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.

### Claim 11 (depends on 3)

A detecting or typing method for high-risk HPV, wherein the method comprises the following steps: detecting a sample to-be-detected with the kit according to claim 3, to divide the high risk type HPV into HPV 16, 18 type groups or HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 type groups.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the detecting or typing method comprises:
(1) Melting the DNA sample to be detected into single chain, mixing with the probe reagent A and the probe reagent B respectively, to obtain hybridization solution A and hybridization solution B;
(2) Loading the hybridization solution A and the hybridization solution B respectively to solid-phase carrier A and solid-phase carrier B coated with capture antibody; forming a capture antibody and DNA-RNA heterozygote binary complex on the solid phase carrier A and the solid phase carrier B;
(2) Loading the detection antibody on a solid phase carrier, and forming ternary complex of capture antibody, DNA-RNA heterozygote and a detection antibody;
(3) Identifying the detectable signals on the solid-phase carriers A and B; determining whether a high-risk HPV virus exists in the sample to be detected; dividing the high risk type HPV into HPV 16, 18 type groups or HPV31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 type groups.
